Q-omics provides the consensus-scored TRBV30 profile across patient tissues and cancer cell-line models. TRBV30 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, TRBV30 is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, TRBV30 RNA expression shows 13,167 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight HNSC, KIRC, and TGCT as cancer lineages where TRBV30 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRBV30 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRBV30 survival associations across molecular data types. TRBV30 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRBV30 RNA expression–survival associations across cancer types. High TRBV30 expression shows unfavorable associations in LGG, but favorable associations in HNSC, SKCM, BLCA, CESC and LUAD. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for TRBV30 RNA expression.
This table summarizes TRBV30 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for TRBV30. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRBV30 shows lower tumor expression in THCA and LUSC and higher tumor expression in KIRC, CHOL, BRCA and STAD. The KIRC box plot shows higher TRBV30 RNA expression in tumor versus normal tissue (log2 FC = +0.915, t-test p < 0.001).
This table shows molecular features associated with TRBV30 in patient tissues and cancer cell lines. In patient samples, TRBV30 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
